NeilEKayMD

PubMed

• 396 citations
  GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
  Rosalie M. Sterner, Reona Sakemura, Michelle J. Cox, Nan Yang, Roman H. Khadka
  Blood. 2019-02-14
• 21 citations
  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients
  Renee C. Tschumper, Susan Geyer, Megan E. Campbell, Neil E. Kay, Tait D. Shanafelt
  The Journal of Clinical Investigation. 2008-01-02
• 1523 citations
  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
  Bruce D. Cheson, John M. Bennett, Michael R. Grever, Neil E. Kay, Michael J. Keating
  Blood. 1996-06-15

Journal Articles

• GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation but Enhances CAR-T Cell Function in Xenografts  
  Aaron J Johnson, Rosalie M Sterner, Neil E Kay, Blood
• Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre  
  Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
• Analytical Considerations in Nanoscale Flow Cytometry of Extracellular Vesicles to Achieve Data Linearity  
  Neil Kay, MD, Thrombosis and Haemostasis

Abstracts/Posters

• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Role for TNF-_ in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• _-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL)
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition is Mechanistically Supported By a Novel Direct Interaction of G...
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity
  Neil E. Kay, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same C... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunothe... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all